advertisement
Pharmaceutics 58
Showing records 1 to 25 | Display all abstracts in Pharmaceutics107919 Chitosan-Covered Calcium Phosphate Particles Co-Loaded with Superoxide Dismutase 1 and ACE Inhibitor: Development, Characterization and Effect on Intraocular Pressure
Popova E
Pharmaceutics 2023; 15:
107918 Design, Characterization and Pharmacokinetic-Pharmacodynamic Evaluation of Poloxamer and Kappa-Carrageenan-Based Dual-Responsive In Situ Gel of Nebivolol for Treatment of Open-Angle Glaucoma
Rawat PS
Pharmaceutics 2023; 15:
108246 Nanocarriers for the Delivery of Neuroprotective Agents in the Treatment of Ocular Neurodegenerative Diseases
Patel C
Pharmaceutics 2023; 15:
107917 The Antibiotic Kitasamycin-A Potential Agent for Specific Fibrosis Preventing Therapy after Fistulating Glaucoma Surgery?
Sterenczak KA
Pharmaceutics 2023; 15:
107916 Optimisation of AAV-NDI1 Significantly Enhances Its Therapeutic Value for Correcting Retinal Mitochondrial Dysfunction
Chadderton N
Pharmaceutics 2023; 15:
108245 Synthesis of Schiff Bases Containing Phenol Rings and Investigation of Their Antioxidant Capacity, Anticholinesterase, Butyrylcholinesterase, and Carbonic Anhydrase Inhibition Properties
Aytac S
Pharmaceutics 2023; 15:
107920 Recent Progress in Chitosan-Based Nanomedicine for Its Ocular Application in Glaucoma
Albarqi HA
Pharmaceutics 2023; 15:
108247 Travoprost Liquid Nanocrystals: An Innovative Armamentarium for Effective Glaucoma Therapy
El-Gendy MA
Pharmaceutics 2023; 15:
108510 Cannabinoid-Based Ocular Therapies and Formulations
Saraiva SM
Pharmaceutics 2023; 15:
107920 Recent Progress in Chitosan-Based Nanomedicine for Its Ocular Application in Glaucoma
Garg A
Pharmaceutics 2023; 15:
108247 Travoprost Liquid Nanocrystals: An Innovative Armamentarium for Effective Glaucoma Therapy
Mansour M
Pharmaceutics 2023; 15:
108510 Cannabinoid-Based Ocular Therapies and Formulations
Martín-Banderas L
Pharmaceutics 2023; 15:
107919 Chitosan-Covered Calcium Phosphate Particles Co-Loaded with Superoxide Dismutase 1 and ACE Inhibitor: Development, Characterization and Effect on Intraocular Pressure
Matveeva O
Pharmaceutics 2023; 15:
107918 Design, Characterization and Pharmacokinetic-Pharmacodynamic Evaluation of Poloxamer and Kappa-Carrageenan-Based Dual-Responsive In Situ Gel of Nebivolol for Treatment of Open-Angle Glaucoma
Ravi PR
Pharmaceutics 2023; 15:
108245 Synthesis of Schiff Bases Containing Phenol Rings and Investigation of Their Antioxidant Capacity, Anticholinesterase, Butyrylcholinesterase, and Carbonic Anhydrase Inhibition Properties
Gundogdu O
Pharmaceutics 2023; 15:
107916 Optimisation of AAV-NDI1 Significantly Enhances Its Therapeutic Value for Correcting Retinal Mitochondrial Dysfunction
Palfi A
Pharmaceutics 2023; 15:
108246 Nanocarriers for the Delivery of Neuroprotective Agents in the Treatment of Ocular Neurodegenerative Diseases
Pande S
Pharmaceutics 2023; 15:
107917 The Antibiotic Kitasamycin-A Potential Agent for Specific Fibrosis Preventing Therapy after Fistulating Glaucoma Surgery?
Fuellen G
Pharmaceutics 2023; 15:
107920 Recent Progress in Chitosan-Based Nanomedicine for Its Ocular Application in Glaucoma
Ahmad MZ
Pharmaceutics 2023; 15:
108247 Travoprost Liquid Nanocrystals: An Innovative Armamentarium for Effective Glaucoma Therapy
El-Assal MIA
Pharmaceutics 2023; 15:
108245 Synthesis of Schiff Bases Containing Phenol Rings and Investigation of Their Antioxidant Capacity, Anticholinesterase, Butyrylcholinesterase, and Carbonic Anhydrase Inhibition Properties
Bingol Z
Pharmaceutics 2023; 15:
107917 The Antibiotic Kitasamycin-A Potential Agent for Specific Fibrosis Preventing Therapy after Fistulating Glaucoma Surgery?
Jünemann A
Pharmaceutics 2023; 15:
107916 Optimisation of AAV-NDI1 Significantly Enhances Its Therapeutic Value for Correcting Retinal Mitochondrial Dysfunction
Maloney DM
Pharmaceutics 2023; 15:
108510 Cannabinoid-Based Ocular Therapies and Formulations
Durán-Lobato M
Pharmaceutics 2023; 15:
108246 Nanocarriers for the Delivery of Neuroprotective Agents in the Treatment of Ocular Neurodegenerative Diseases
Sagathia V
Pharmaceutics 2023; 15:
